|
Correlation of tumor mutational burden (TMB) with CDKN2A and TP53 mutation in HPV-negative head and neck squamous cell carcinoma (HNSCC). |
|
|
|
Consulting or Advisory Role - Aduro Biotech; Alligator Bioscience; ALX Oncology; AstraZeneca; Bristol-Myers Squibb; Celgene; CUE Biopharma; Debiopharm Group; GlaxoSmithKline; Macrogenics; Maverick Therapeutics; Merck; Nanobiotix; Rakuten Medical |
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Formation Biologics (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Debiopharm Group; Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Immunomedics |
Consulting or Advisory Role - Bayer; Eisai |
Speakers' Bureau - Eisai; Merck |
Research Funding - Eisai (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |